JP2019500909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500909A5 JP2019500909A5 JP2018555310A JP2018555310A JP2019500909A5 JP 2019500909 A5 JP2019500909 A5 JP 2019500909A5 JP 2018555310 A JP2018555310 A JP 2018555310A JP 2018555310 A JP2018555310 A JP 2018555310A JP 2019500909 A5 JP2019500909 A5 JP 2019500909A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- strain
- inhibitor
- agonist
- accession number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1600382.4 | 2016-01-08 | ||
| GBGB1600380.8A GB201600380D0 (en) | 2016-01-08 | 2016-01-08 | Modified virus |
| GBGB1600381.6A GB201600381D0 (en) | 2016-01-08 | 2016-01-08 | Virus strain |
| GB1600381.6 | 2016-01-08 | ||
| GBGB1600382.4A GB201600382D0 (en) | 2016-01-08 | 2016-01-08 | Engineered virus |
| GB1600380.8 | 2016-01-08 | ||
| PCT/GB2017/050037 WO2017118865A1 (en) | 2016-01-08 | 2017-01-09 | Oncolytic virus strain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500909A JP2019500909A (ja) | 2019-01-17 |
| JP2019500909A5 true JP2019500909A5 (enExample) | 2020-01-30 |
| JP7038065B2 JP7038065B2 (ja) | 2022-03-17 |
Family
ID=57796748
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555311A Active JP7038664B2 (ja) | 2016-01-08 | 2017-01-09 | 操作された腫瘍溶解性ウイルス |
| JP2018555310A Active JP7038065B2 (ja) | 2016-01-08 | 2017-01-09 | 腫瘍溶解性ウイルス株 |
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555311A Active JP7038664B2 (ja) | 2016-01-08 | 2017-01-09 | 操作された腫瘍溶解性ウイルス |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Country Status (13)
| Country | Link |
|---|---|
| US (13) | US10570377B2 (enExample) |
| EP (8) | EP3400290B1 (enExample) |
| JP (8) | JP7038664B2 (enExample) |
| KR (2) | KR20250026348A (enExample) |
| CN (3) | CN109153977B (enExample) |
| AU (2) | AU2017205216B2 (enExample) |
| CA (3) | CA3011009A1 (enExample) |
| DK (4) | DK3400291T4 (enExample) |
| ES (4) | ES2831080T5 (enExample) |
| IL (2) | IL260480B (enExample) |
| MX (1) | MX2018008413A (enExample) |
| SG (2) | SG10202108724YA (enExample) |
| WO (4) | WO2017118865A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60115600T2 (de) * | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
| JP2010529820A (ja) | 2007-05-31 | 2010-08-26 | クリシュナン ラム | 最小限の固定子鉄心を備えたスイッチドリラクタンス機 |
| NZ711946A (en) | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR112018000917A2 (pt) | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| EP3400290B1 (en) * | 2016-01-08 | 2023-04-05 | Replimune Limited | Oncolytic virus strain |
| AR107469A1 (es) | 2016-01-27 | 2018-05-02 | Oncorus Inc | Vectores virales oncolíticos y sus usos |
| RU2748378C2 (ru) | 2016-03-16 | 2021-05-25 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| CN108350468B (zh) * | 2016-04-22 | 2020-10-30 | 深圳市亦诺微医药科技有限公司 | 用于癌症治疗的溶瘤性单纯疱疹病毒(oHSV)专性载体及其构建体的构建 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| WO2018006005A1 (en) * | 2016-06-30 | 2018-01-04 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN110678750A (zh) | 2017-04-28 | 2020-01-10 | 美国默沙东药厂 | 用于癌症治疗的生物标志物 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3070299A1 (en) | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| JP7079171B2 (ja) | 2017-08-03 | 2022-06-01 | アムジエン・インコーポレーテツド | インターロイキン－２１ムテイン及び治療方法 |
| MX2020002502A (es) | 2017-09-08 | 2020-07-20 | Amgen Inc | Inhibidores de kras g12c y metodos para utilizarlos. |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| EP3708657A4 (en) * | 2017-11-08 | 2021-08-25 | Kagoshima University | ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL |
| EP3710035A4 (en) * | 2017-11-13 | 2021-12-29 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| US11518808B2 (en) | 2018-01-12 | 2022-12-06 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
| WO2019147982A1 (en) * | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| CA3103371A1 (en) * | 2018-06-21 | 2019-12-26 | Replimune Limited | Treatment using oncolytic virus |
| WO2020006486A1 (en) * | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| WO2020052551A1 (en) * | 2018-09-10 | 2020-03-19 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
| KR20210065976A (ko) * | 2018-09-26 | 2021-06-04 | 아스텔라스세이야쿠 가부시키가이샤 | 종양 용해성 백시니아 바이러스와 면역 체크포인트 저해제의 병용에 의한 암 요법 그리고 이것에 사용하기 위한 의약 조성물 및 조합 의약 |
| JP7566750B2 (ja) | 2018-12-27 | 2024-10-15 | アムジェン インコーポレイテッド | 凍結乾燥ウイルス製剤 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| EP3935182A1 (en) * | 2019-03-05 | 2022-01-12 | Amgen Inc. | Use of oncolytic viruses for the treatment of cancer |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| CN110054678B (zh) * | 2019-05-16 | 2023-04-18 | 中国医学科学院血液病医院（血液学研究所） | 一种膜结合型mFLT3LG蛋白及其应用 |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| KR20220044310A (ko) * | 2019-08-05 | 2022-04-07 | 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 | 악성 종양을 치료하기 위한 병용약, 악성 종양을 치료하기 위한 의약 조성물 및 악성 종양 치료용 의약 조성물 |
| CA3156880A1 (en) * | 2019-11-06 | 2021-05-14 | Memgen, Inc. | Replication-enhanced oncolytic adenoviruses |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| WO2021175293A1 (zh) * | 2020-03-05 | 2021-09-10 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| WO2021193081A1 (ja) * | 2020-03-23 | 2021-09-30 | 国立大学法人東海国立大学機構 | １型単純ヘルペスウイルス |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| DE102022104146A1 (de) | 2021-03-19 | 2022-09-22 | Yamada Manufacturing Co., Ltd. | Lenkvorrichtung |
| US20240191252A1 (en) * | 2021-04-08 | 2024-06-13 | Immvira Biopharmaceuticals Co., Limited | Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen |
| US20240245739A1 (en) * | 2021-05-18 | 2024-07-25 | The Penn State Research Foundation | Oncolytic virus based cancer therapy |
| CN113583979B (zh) * | 2021-08-03 | 2022-11-22 | 杭州荣谷生物科技有限公司 | 一种重组溶瘤痘苗病毒、制备方法及其用途 |
| WO2023136212A1 (ja) | 2022-01-11 | 2023-07-20 | 三菱マテリアル株式会社 | 表面被覆切削工具 |
| WO2024055022A2 (en) * | 2022-09-08 | 2024-03-14 | Virogin Biotech Canada Ltd | Oncolytic virus expressing an immune cell engager for tumor targeting |
| WO2025248110A1 (en) * | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| DE69332525T2 (de) | 1992-03-31 | 2003-04-17 | Arch Development Corp., Chicago | Behandlung von Tumorerkrankungen mit modifiziertem HSV |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| CA2234060A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| CA2388807C (en) | 1999-11-12 | 2013-08-06 | Matthew C. Coffey | Viruses for the treatment of cellular proliferative disorders |
| DE60115600T2 (de) | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| ATE508635T1 (de) | 2001-03-27 | 2011-05-15 | Catherex Inc | Virusvektoren und ihre verwendung bei therapeutischen methoden |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| MX2007003804A (es) | 2004-11-04 | 2007-04-23 | Pfizer Prod Inc | Tratamiento combinado de anticuerpo anti-ctla4 e inhibidor de aromatasa para el cancer de mama. |
| US9866961B2 (en) | 2004-12-01 | 2018-01-09 | Todd Beauchamp | Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers |
| LT2620450T (lt) | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| HUE029789T2 (en) | 2005-05-06 | 2017-04-28 | Providence Health & Services - Oregon | Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| JP2013511549A (ja) | 2009-11-20 | 2013-04-04 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | ヘッジホッグ関連癌の治療のための方法及び組成物 |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| PT2753355T (pt) * | 2011-09-08 | 2019-02-01 | Univ New York | Vírus herpes simplex oncolítico e suas utilizações terapêuticas |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| EP2806883B1 (en) * | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| EP2879498A4 (en) | 2012-07-30 | 2016-03-30 | Alex Wah Hin Yeung | BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM |
| EP2890714A2 (en) | 2012-08-30 | 2015-07-08 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| NZ711946A (en) | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| PT3508209T (pt) | 2013-09-03 | 2022-05-27 | Medimmune Ltd | Composições que apresentam um vírus da doença de newcastle atenuado e métodos de utilização para o tratamento de neoplasias |
| TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
| CN106068326B (zh) | 2013-10-28 | 2021-06-18 | 联邦高等教育系统-匹兹堡大学 | 溶瘤性hsv载体 |
| WO2015077624A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| MA39818A (fr) * | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
| CA3190510A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
| US20160040186A1 (en) | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| US10525557B2 (en) | 2015-01-23 | 2020-01-07 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| EP3400290B1 (en) | 2016-01-08 | 2023-04-05 | Replimune Limited | Oncolytic virus strain |
| CN108350468B (zh) | 2016-04-22 | 2020-10-30 | 深圳市亦诺微医药科技有限公司 | 用于癌症治疗的溶瘤性单纯疱疹病毒(oHSV)专性载体及其构建体的构建 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US12029647B2 (en) * | 2017-03-07 | 2024-07-09 | 4C Medical Technologies, Inc. | Systems, methods and devices for prosthetic heart valve with single valve leaflet |
| CA3103371A1 (en) | 2018-06-21 | 2019-12-26 | Replimune Limited | Treatment using oncolytic virus |
| SG11202106460XA (en) | 2018-12-21 | 2021-07-29 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
-
2017
- 2017-01-09 EP EP17700384.5A patent/EP3400290B1/en active Active
- 2017-01-09 CN CN201780012759.3A patent/CN109153977B/zh active Active
- 2017-01-09 EP EP17700385.2A patent/EP3400291B2/en active Active
- 2017-01-09 SG SG10202108724YA patent/SG10202108724YA/en unknown
- 2017-01-09 CN CN201780012527.8A patent/CN109415703B/zh active Active
- 2017-01-09 ES ES17701910T patent/ES2831080T5/es active Active
- 2017-01-09 US US16/068,826 patent/US10570377B2/en active Active
- 2017-01-09 DK DK17700385.2T patent/DK3400291T4/da active
- 2017-01-09 EP EP17700386.0A patent/EP3400292B1/en active Active
- 2017-01-09 EP EP20197725.3A patent/EP3805376B1/en active Active
- 2017-01-09 AU AU2017205216A patent/AU2017205216B2/en active Active
- 2017-01-09 US US16/068,830 patent/US10947513B2/en active Active
- 2017-01-09 WO PCT/GB2017/050037 patent/WO2017118865A1/en not_active Ceased
- 2017-01-09 WO PCT/GB2017/050036 patent/WO2017118864A1/en not_active Ceased
- 2017-01-09 KR KR1020257002985A patent/KR20250026348A/ko active Pending
- 2017-01-09 WO PCT/GB2017/050038 patent/WO2017118866A1/en not_active Ceased
- 2017-01-09 KR KR1020187022799A patent/KR102762431B1/ko active Active
- 2017-01-09 DK DK20197725.3T patent/DK3805376T3/da active
- 2017-01-09 JP JP2018555311A patent/JP7038664B2/ja active Active
- 2017-01-09 MX MX2018008413A patent/MX2018008413A/es unknown
- 2017-01-09 DK DK17700384.5T patent/DK3400290T5/da active
- 2017-01-09 US US16/068,823 patent/US10626377B2/en active Active
- 2017-01-09 JP JP2018555310A patent/JP7038065B2/ja active Active
- 2017-01-09 CA CA3011009A patent/CA3011009A1/en active Pending
- 2017-01-09 EP EP23156055.8A patent/EP4219696A3/en active Pending
- 2017-01-09 EP EP25185492.3A patent/EP4628577A2/en active Pending
- 2017-01-09 WO PCT/GB2017/050039 patent/WO2017118867A1/en not_active Ceased
- 2017-01-09 ES ES17700385T patent/ES2841300T5/es active Active
- 2017-01-09 EP EP17701910.6A patent/EP3400293B2/en active Active
- 2017-01-09 SG SG11201805835WA patent/SG11201805835WA/en unknown
- 2017-01-09 CN CN201780012579.5A patent/CN109312309B/zh active Active
- 2017-01-09 DK DK17701910.6T patent/DK3400293T4/da active
- 2017-01-09 ES ES17700384T patent/ES2943150T3/es active Active
- 2017-01-09 ES ES20197725T patent/ES3041885T3/es active Active
- 2017-01-09 JP JP2018555309A patent/JP6959258B2/ja active Active
- 2017-01-09 US US16/068,816 patent/US10612005B2/en active Active
- 2017-01-09 CA CA3010987A patent/CA3010987A1/en active Pending
- 2017-01-09 CA CA3011004A patent/CA3011004A1/en active Pending
- 2017-01-09 EP EP20189881.4A patent/EP3778881A1/en active Pending
-
2018
- 2018-07-08 IL IL260480A patent/IL260480B/en active IP Right Grant
-
2020
- 2020-01-10 US US16/740,203 patent/US11473063B2/en active Active
- 2020-02-24 US US16/799,090 patent/US11427810B2/en active Active
-
2021
- 2021-02-01 US US17/164,635 patent/US12049647B2/en active Active
- 2021-05-06 IL IL282985A patent/IL282985B/en unknown
- 2021-10-05 JP JP2021163811A patent/JP7295192B2/ja active Active
-
2022
- 2022-03-07 JP JP2022034569A patent/JP2022078225A/ja active Pending
- 2022-08-03 US US17/817,245 patent/US12458696B2/en active Active
- 2022-08-04 US US17/817,618 patent/US12024724B2/en active Active
- 2022-12-01 AU AU2022279486A patent/AU2022279486B2/en active Active
-
2023
- 2023-02-02 US US18/163,837 patent/US12397053B2/en active Active
- 2023-06-08 JP JP2023094818A patent/JP2023113885A/ja active Pending
- 2023-09-06 US US18/462,133 patent/US12465639B2/en active Active
-
2024
- 2024-05-21 US US18/670,296 patent/US20240301365A1/en active Pending
- 2024-07-25 JP JP2024119344A patent/JP2024153748A/ja active Pending
-
2025
- 2025-07-23 US US19/277,600 patent/US20250352646A1/en active Pending
- 2025-07-31 JP JP2025128636A patent/JP2025163138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500909A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| JP2019501671A5 (enExample) | ||
| JP7295192B2 (ja) | 改変された腫瘍溶解性ウイルス | |
| US20240091256A1 (en) | Genetic engineering of macrophages for immunotherapy | |
| Nguyen et al. | Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy | |
| Guo et al. | Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives | |
| Pol et al. | Trial Watch—Oncolytic viruses and cancer therapy | |
| JP2020503871A5 (enExample) | ||
| JP2024095709A5 (enExample) | ||
| JP7520511B2 (ja) | 改変ウイルス | |
| Humeau et al. | Trial watch: intratumoral immunotherapy | |
| Yan et al. | Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments | |
| US20210252135A1 (en) | Treatment using oncolytic virus | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| Martini et al. | Oncolytic virotherapy: new weapon for breast cancer treatment | |
| JP7754891B2 (ja) | Ｃｃｌ２１をコードする組換えラブドウイルス | |
| Wang et al. | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | |
| JPWO2019243847A5 (enExample) | ||
| Lecoultre et al. | Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | |
| Shakiba et al. | Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy | |
| Tada et al. | Directly injected lentiviral vector–based T cell vaccine protects mice against acute and chronic viral infection | |
| Ghosh et al. | Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions | |
| Lasek et al. | Interleukin 12: Antitumor activity and immunotherapeutic potential in oncology | |
| US20240366696A1 (en) | Using reprogrammed, personalized cancer stem cells as a triple-killer cancer treatment |